Marshall Wace North America’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

Marshall Wace North America’s Portfolio MRNS Stock Details MRNS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-16,995	Closed	-$195K	–	1981
2018 Q4	$195K	Buy	+16,995	New	+$344K	﹤0.01%	963
2018 Q3	–	Sell	-94,868	Closed	-$2.68M	–	1458
2018 Q2	$2.68M	Buy	94,868 +70,978	+297%	+$1.57M	0.02%	687
2018 Q1	$365K	Buy	23,890 +18,330	+330%	+$436K	﹤0.01%	1226
2017 Q4	$181K	Sell	5,560 -61,241	-92%	-$1.65M	﹤0.01%	1296
2017 Q3	$1.6M	Buy	+66,801	New	+$749K	0.01%	853

Other funds holding MRNS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

VMI

VHCP Management III New York $504M AUM 683.12% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

Marshall Wace North America's MRNS Position: Q1 2019 in Review

Marshall Wace North America sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2019, closing a stake of 16,995 shares — an estimated $195K sold.

Marshall Wace North America first reported a position in MRNS in Q3 2017 and held it in 5 quarters. The position peaked at $2.68M in Q2 2018. 81 funds tracked by Wall St. Rank hold MRNS as of Q1 2019.

Marshall Wace North America reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2019 after selling out during the quarter.
Marshall Wace North America sold 16,995 Marinus Pharmaceuticals, Inc shares in Q1 2019, an estimated $195K.
Marshall Wace North America first reported a position in Marinus Pharmaceuticals, Inc in Q3 2017 and held it in 5 quarters.
Marshall Wace North America's Marinus Pharmaceuticals, Inc position peaked at $2.68M in Q2 2018.
81 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2019.

Based on Marshall Wace North America's 13F filing for Q1 2019, filed 14 May 2019.